Androgen Deprivation Therapy for Radiation

Androgen Deprivation Therapy (ADT) reduces levels of male hormones—primarily testosterone—that can stimulate prostate cancer growth. It is often used alongside radiation therapy to improve treatment outcomes, especially in intermediate- and high-risk prostate cancer cases.

Prostate cancer cells rely on androgens to grow. ADT can be achieved with medications that block testosterone production (LHRH agonists/antagonists) or through surgical removal of the testes (rare today). Lowering androgen levels weakens cancer cells, making them more sensitive to radiation and reducing the chance of recurrence.

ADT may begin several months before radiation and continue during and after treatment. Duration ranges from 4–6 months for some intermediate-risk patients to up to 2–3 years for higher-risk cases, based on individual treatment plans.

No major preparation is needed, but your doctor may recommend blood tests, bone health evaluation, and baseline hormone level checks before starting therapy. You should discuss all medications, supplements, and medical history with your care team.

• Hot flashes and night sweats
• Reduced libido and erectile dysfunction
• Fatigue
• Loss of muscle mass and bone density
• Weight gain and metabolic changes
• Mood changes

These side effects are manageable, and your care team will provide strategies to maintain quality of life during treatment.

ADT significantly improves cancer control when combined with radiation, reducing recurrence and prolonging survival in many patients. Risks include long-term hormonal side effects and potential cardiovascular or bone health impacts, which will be monitored during follow-up visits.